Acurx Pharmaceuticals Inc Financials
This page shows Acurx Pharmaceuticals Inc (ACXP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Acurx’s capital-funded operating model persists: losses consume cash while financing reshapes a balance sheet weakened in FY2024.
The gap between FY2025 net loss and operating cash flow was$1.2M versus$3.7M in FY2024, showing accounting losses are translating more directly into cash needs. That tighter alignment coincided with R&D declining from$5.4M to$1.8M , so the improvement reflects reduced spending more than evidence of commercial scale.
FY2024 liabilities of
The company generated
Financial Health Signals
Acurx Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Acurx Pharmaceuticals Inc passes 3 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.
Acurx Pharmaceuticals Inc reported a net loss of $8.0M while operations used $6.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Acurx Pharmaceuticals Inc reported -$8.0M in net income in fiscal year 2025. This represents an increase of 43.5% from the prior year.
Acurx Pharmaceuticals Inc earned -$5.32 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Acurx Pharmaceuticals Inc held $7.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Acurx Pharmaceuticals Inc's ROE was -151.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 2141.5 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Acurx Pharmaceuticals Inc invested $1.8M in research and development in fiscal year 2025. This represents a decrease of 66.1% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ACXP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.1M+213.8% | $341K | N/A | $430K-18.0% | $524K-12.5% | $599K | N/A | $1.2M |
| SG&A Expenses | $1.2M-10.1% | $1.4M | N/A | $1.6M-8.4% | $1.7M+10.6% | $1.6M | N/A | $1.6M |
| Operating Income | -$2.3M-34.5% | -$1.7M | N/A | -$2.0M+10.6% | -$2.3M-4.3% | -$2.2M | N/A | -$2.8M |
| Net Income | -$2.3M-34.1% | -$1.7M | N/A | -$2.0M+11.3% | -$2.2M-4.5% | -$2.1M | N/A | -$2.8M |
| EPS (Diluted) | -$0.53 | -$0.62-100.0% | -$0.31+74.8% | -$1.23+34.9% | -$1.89 | -$2.15+33.2% | -$3.22+6.7% | -$3.45 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
ACXP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.0M+15.1% | $9.5M+24.1% | $7.7M+26.0% | $6.1M-0.9% | $6.2M+28.1% | $4.8M+24.6% | $3.9M-35.5% | $6.0M |
| Current Assets | N/A | N/A | N/A | N/A | $6.2M+28.1% | $4.8M+24.6% | $3.9M-35.5% | $6.0M |
| Cash & Equivalents | $10.7M+15.1% | $9.3M+22.5% | $7.6M+27.9% | $5.9M-2.6% | $6.1M+30.6% | $4.6M+25.3% | $3.7M-35.7% | $5.8M |
| Total Liabilities | $2.8M+12.1% | $2.5M+4.4% | $2.4M-1.9% | $2.5M-4.8% | $2.6M+3.9% | $2.5M-23.1% | $3.2M-2.3% | $3.3M |
| Current Liabilities | $2.8M+12.1% | $2.5M+4.4% | $2.4M-1.9% | $2.5M-4.8% | $2.6M+3.9% | $2.5M-23.1% | $3.2M-2.3% | $3.3M |
| Total Equity | $8.2M+16.2% | $7.0M+33.1% | $5.3M+44.9% | $3.6M+2.0% | $3.6M+54.3% | $2.3M+275.8% | $615K-76.9% | $2.7M |
| Retained Earnings | -$79.2M-2.9% | -$77.0M-2.2% | -$75.3M-2.1% | -$73.7M-2.8% | -$71.7M-3.2% | -$69.5M-3.2% | -$67.3M-4.3% | -$64.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ACXP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M-21.5% | -$1.4M-18.8% | -$1.2M+37.0% | -$1.9M-12.6% | -$1.7M+18.6% | -$2.1M+8.8% | -$2.3M-2.8% | -$2.2M |
| Financing Cash Flow | $3.1M+0.2% | $3.1M+9.6% | $2.8M+64.4% | $1.7M-44.2% | $3.1M+3.4% | $3.0M+1436.2% | $195K-87.8% | $1.6M |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
ACXP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -27.7%-3.7pp | -24.0% | N/A | -54.8%+8.2pp | -63.0%+30.0pp | -93.0% | N/A | -105.9% |
| Return on Assets | -20.5%-2.9pp | -17.6% | N/A | -32.6%+3.8pp | -36.5%+8.2pp | -44.7% | N/A | -47.2% |
| Current Ratio | N/A | N/A | N/A | N/A | 2.38+0.4x | 1.93+0.7x | 1.19-0.6x | 1.80 |
| Debt-to-Equity | 0.350.0x | 0.36-0.1x | 0.46-0.2x | 0.680.0x | 0.73-0.4x | 1.08-4.2x | 5.27+4.0x | 1.25 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Acurx Pharmaceuticals Inc Ranks
Frequently Asked Questions
Is Acurx Pharmaceuticals Inc profitable?
No, Acurx Pharmaceuticals Inc (ACXP) reported a net income of -$8.0M in fiscal year 2025.
What is Acurx Pharmaceuticals Inc's return on equity (ROE)?
Acurx Pharmaceuticals Inc (ACXP) has a return on equity of -151.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Acurx Pharmaceuticals Inc's operating cash flow?
Acurx Pharmaceuticals Inc (ACXP) recorded an outflow of $6.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Acurx Pharmaceuticals Inc's total assets?
Acurx Pharmaceuticals Inc (ACXP) had $7.7M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Acurx Pharmaceuticals Inc spend on research and development?
Acurx Pharmaceuticals Inc (ACXP) invested $1.8M in research and development during fiscal year 2025.
What is Acurx Pharmaceuticals Inc's debt-to-equity ratio?
Acurx Pharmaceuticals Inc (ACXP) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Acurx Pharmaceuticals Inc's return on assets (ROA)?
Acurx Pharmaceuticals Inc (ACXP) had a return on assets of -103.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Acurx Pharmaceuticals Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Acurx Pharmaceuticals Inc (ACXP) held $7.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.8M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Acurx Pharmaceuticals Inc's Piotroski F-Score?
Acurx Pharmaceuticals Inc (ACXP) has a Piotroski F-Score of 3 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Acurx Pharmaceuticals Inc's earnings high quality?
Acurx Pharmaceuticals Inc (ACXP) reported a net loss of $8.0M while operations used $6.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.